Overview

Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer

Status:
Terminated
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether or not the addition of Herceptin may be of benefit to a standard regimen of carboplatin-paclitaxel.
Phase:
Phase 2
Details
Lead Sponsor:
ARCAGY/ GINECO GROUP
Collaborator:
Hoffmann-La Roche
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel
Trastuzumab